Agenda
13-16 October 2025
RAI Congress Centre, Amsterdam
Amsterdam, 13 - 16 October 2025
Schedule
Create your personal agenda –check the favourite icon
Oct 1310:00
Conference pass
Platform Technologies Workshop [AM1]
Platform Technologies Workshop
Jeffrey Almond, Former VP Discovery R&D, Sanofi & Visiting Professor, University of Oxford - Oxford Vaccine Group
Robbert Van der Most, CEO, Vaxxcellence
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Session led by: 
Session led by: 
Oct 1310:00
Conference pass
Biothreats & Disease X Workshop [AM2]
Biothreats & Disease X Workshop
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Oct 1313:00
Conference pass
Lunch & Networking Break
Exhibition & Networking
Afternoon Workshops Begin at 2pm:
- Vaccine Safety
- Vaccine Delivery
- Special Populations
Oct 1314:00
Conference pass
Vaccine Safety Workshop [PM1]
Vaccine Safety Workshop
Christine Stabell Benn, Professor, University of Southern Denmark
Peter Aaby, Professor & Founder, Bandim Health Project
Oct 1314:00
Conference pass
Special Populations Workshop [PM2]
Special Populations Workshop
Kirsten Maertens, Assistant Professor, Vaccines & Infectious Disease Institute, University of Antwerp
Oct 1314:00
Conference pass
Vaccine Delivery Workshop [PM3]
Vaccine Delivery Workshop
Maria Alriksson, CEO, Abera Bioscience AB
Create your personal agenda –check the favourite icon
Oct 149:00
Conference pass
Beyond Borders: Europe’s Strategic Role in Powering Vaccine Innovation and Transforming the Global Vaccine Landscape
Keynotes
- How can Europe’s unique ecosystem of innovation hubs, regulatory frameworks, and public-private partnerships accelerate the next generation of breakthrough vaccines?
- What strategies and incentives are needed to transform Europe’s emerging biotechs and SMEs into tomorrow’s vaccine innovation leaders?
- How can regulatory frameworks evolve to support rapid innovation while maintaining the gold standard in vaccine safety and efficacy?
- In an increasingly complex global health landscape, how can Europe balance domestic innovation priorities with its responsibility to ensure equitable worldwide vaccine access?
Wolfgang Philipp, Principal Adviser, Chief Science Officer, European Commission Health Emergency Preparedness & Response (HERA)
Oct 1410:00
Conference pass
Rebuilding Public Literacy and Trust in an Era of Polarisation and Political Uncertainty
Keynotes
- The global impact of U.S. vaccine policy shifts: how political narratives in the U.S. are shaping vaccine confidence and policies worldwide
- The role of governments, media, and public health leaders: what tangible steps can be taken to counter vaccine scepticism and rebuild trust in science?
- What evidence-based strategies are actually working to rebuild trust and increase vaccine uptake in highly polarised environments?
- Tailoring communication approaches to address vaccine hesitancy in different cultural, socioeconomic, and political contexts
- Balancing public health needs with individual freedoms in vaccine policymaking and communication.
- In an increasingly fragmented world, how can we build sustainable cross-border collaborations to strengthen vaccine confidence and literacy?
- Looking ahead: What does the future hold for vaccine policy, funding, and global collaboration in a politically fragmented world?
Oct 1411:00
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1411:30
Conference pass
Adoption and utilization of virus neutralization assays: Challenges and best practices
Working Groups
Session led by: 
Oct 1411:30
Conference pass
IVI Working Group
Working Groups
Session led by: 
Oct 1411:30
Conference pass
Rising Stars: Empowering Mid-Career Women in Global Immunisation Leadership
Working Groups
- What challenges do mid-career women face when transitioning into leadership roles in immunisation?
- How can we support professional growth and visibility for women in vaccine R&D and policy?
- Lessons from Women Lift Health & other networks
- How do gender representation and equity shape immunisation policy and leadership?
- Mentorship and networking strategies for career advancement
- Balancing field experience with leadership aspirations
Oct 1412:30
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1414:00
Conference pass
Capturing high quality immunoassay data- case studies using Certimmune
Technology Showcases
Session led by: 
Oct 1414:00
Conference pass
Capillary Devices for Sample Collection in Decentralized Vaccine Studies
COVID & Beyond
Session led by: 
Oct 1414:00
Conference pass
COVID & Beyond Track Chair
COVID & Beyond
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Oct 1414:00
Conference pass
A new animal-free recombinant enzyme for cell-based vaccine production
Formulation & Bioprocess
Session led by: 
Oct 1414:00
Conference pass
AMR & Bacterial Vaccines Track Chair
AMR & Bacterial Vaccines
Oct 1414:00
Conference pass
AMR Funding & Partnerships
AMR & Bacterial Vaccines
Senior Representative, Bactivac
Oct 1414:15
Conference pass
Advanced Technologies in Animal-Free Viral Vaccines Production
Technology Showcases
Session led by: 
Oct 1414:30
Conference pass
GMP NGS for Quality Control Testing of Vaccines
Technology Showcases
Session led by: 
Oct 1414:30
Conference pass
Scaling new heights: ionizable lipids for vaccine development, GMP manufacturing, and clinical success
COVID & Beyond
Oct 1414:30
Conference pass
Ensuring clinical availability of vaccine delivery systems, immunostimulators & combined adjuvant systems
Formulation & Bioprocess
Session led by: 
Oct 1414:30
Conference pass
Advancing Vaccines and Antibodies for Drug-Resistant Infections
AMR & Bacterial Vaccines
- The role of both vs a vs “traditional” antibiotics
- What is in the pipeline / where are the gaps
- Barriers and opportunities to stimulate R&D
Oct 1414:45
Conference pass
Title TBC
Formulation & Bioprocess
Session led by: 
Oct 1415:00
Conference pass
Title TBC
COVID & Beyond
Session led by: 
Oct 1415:15
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1415:45
Conference pass
A scalable cell-free protein production technology accelerating vaccine development
Technology Showcases
Session led by: 
Oct 1415:45
Conference pass
COVID & Beyond Track Chair
COVID & Beyond
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Oct 1415:45
Conference pass
Harnessing Microbial Innovation: The Road to a First-in-Human pan-Sarbecovirus Vaccine
COVID & Beyond
Oct 1415:45
Conference pass
Clinical Data on New Adjuvant AS37, a TLR7 Agonist
Formulation & Bioprocess
Marguerite Koutsoukos, Sr Clinical Science Lead, GSK
Oct 1415:45
Conference pass
AMR & Bacterial Vaccines Track Chair
AMR & Bacterial Vaccines
Oct 1416:00
Conference pass
Title TBC
Technology Showcases
Session led by: 
Oct 1416:00
Conference pass
The Next Coronaviruses as Possible Pandemic Threats
COVID & Beyond
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Oct 1416:00
Conference pass
Adjuvants Panel
Formulation & Bioprocess
Nicolas Collin, Co-Founder and Chief Executive Officer, Vaccine Formulation Institute CH Ltd
Oct 1416:15
Conference pass
Title TBC
Technology Showcases
Session led by: 
Oct 1416:15
Conference pass
The Role of Cellular Immunity in COVID-19 Vaccination: New Insights and Applications
COVID & Beyond
Oct 1416:30
Conference pass
Candidate Vaccines for MERS-CoV and Related Merbecoviruses
COVID & Beyond
Oct 1416:45
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1417:00
Conference pass
AMR: Promoting the alignment of nation action plans and implementation of vaccination strategies across human and animal health
Keynotes
- How do we begin implementing the commitments of the political declaration?
- What are our priority areas and diseases where vaccination can mitigate and prevent AMR?
- Ensuring a multisectoral approach: where will human and animal sectors align and collaborate on their strategies?
Create your personal agenda –check the favourite icon
Oct 159:00
Conference pass
Valuing Vaccines Beyond Cost-Effectiveness
Keynotes
- How can we evolve beyond traditional metrics to capture the full societal value of vaccines - from pandemic prevention to economic stability?
- What would a new multidimensional framework for measuring vaccine impact look like, and how could it transform funding priorities?
- How do we bridge the gap between theoretical frameworks and real-world policy adoption - what are the barriers and opportunities?
- As the world faces new health challenges, how can expanded valuation metrics help drive better decision-making in vaccine development and implementation?
Oct 1510:00
Conference pass
Rethinking Global Health Threats and Responses: H5N1, Mpox, Measles, Marburg, Climate, Zoonoses, and Emerging Risks
Keynotes
- Pandemic vs. endemic priorities: What’s missing from the global agenda? – Are we too fixated on future pandemics while ignoring the growing threats of endemic infectious diseases (e.g., TB, dengue, H5N1)?
- Climate-driven disease risks: Are we accurately predicting which pathogens will surge due to climate change? (e.g., vector-borne diseases like malaria vs. less-discussed threats). How can we better anticipate less obvious threats?
- How should we be investing in surveillance and R&D? – What innovations (AI, genomics, forecasting) actually have the potential to get ahead of the next crisis?
- How do we ensure that disease prioritisation is driven by science, not politics? – What structural and policy shifts are needed to avoid repeating past mistakes?
- Are we adequately investing in diagnostic capabilities for future threats, or are we overly focused on vaccines and treatments? How can improved diagnostic strategies enhance our ability to detect and respond to emerging threats quickly?
- How can we improve international collaboration in disease surveillance, research, and response while addressing geopolitical challenges and ensuring equitable access to resources?
Wolfgang Philipp, Principal Adviser, Chief Science Officer, European Commission Health Emergency Preparedness & Response (HERA)
Oct 1511:00
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1512:45
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1516:45
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Create your personal agenda –check the favourite icon
Oct 169:00
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1611:30
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1614:45
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1615:00
Conference pass
Life-Course Immunisation: Are Combination Vaccines the Only Viable Path Forward for Adults?
Keynotes
- Evaluating the economic and societal case for routine adult and life-course immunisation,
- What next-generation combination vaccines are approaching approval, and when will health systems realistically adopt them?
- Will standalone new vaccines remain viable, or is the future exclusively in combination vaccines?
- Strategies for integrating novel antigens into existing vaccine presentations and delivery systems
- Policy, procurement, and health system strategies to sustainably deliver true life-course immunisation.
last published: 30/Apr/25 13:25 GMT
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events